The Health Plan Blueprint for Network Optimization
Build a network designed to win, with lower costs, higher quality, and market-leading performance. This eBook is a strategic guide for health plan executives aiming to improve network performance, reduce cost of care, and strengthen competitive positioning in a margin-constrained environment. It highlights how underperforming provider networks can leave 2–6% of spend unrealized while outlining […]
10 brands transforming travel and hospitality payments
Dines increased revenue 150% per venue. This guide features 10 travel and hospitality brands—including Alaska Airlines, SeatGeek, and Hertz—on how they’re driving growth with payments. See how they’re increasing conversions, unifying online and in-person channels, capturing revenue beyond core bookings, and expanding globally faster.
AI in Credentialing: 5 principles for getting it right
Healthcare organizations face mounting pressure to modernize provider operations — but credentialing isn’t a generic automation problem. Governed by NCQA, CMS, and payer-specific requirements, these workflows demand more than speed. They require accuracy, oversight, and audit-ready accountability. This guide outlines five principles for evaluating AI in credentialing: purpose-built design for regulated workflows, human oversight that […]
Cancer is changing. Is pharma marketing changing with it?
Early-onset cancers are rising among adults 18–49, challenging long-held assumptions about who cancer affects and how patients need to be reached, supported and understood. The New Age of Cancer explores what this shift means for the oncology ecosystem, and why pharma and health marketers may need to rethink the way they engage a generation of […]
Patient Experience: Operationalizing AI in a Defining Metric
Almost two-thirds of healthcare leaders believe improving patient experience is the area where AI tools will have the greatest impact. In this shift to value-based care, healthcare organizations are embracing a patient-centric model that influences reimbursement and outcomes. Yet, gaps remain even as patient experience scores trend upward. Because not all AI implementations are created […]
Why Multi-Omic Insights Demand a Multi-Omic Strategy
As biomedical research advances, relying on a single data source is no longer enough to uncover the full picture of disease biology. Integrating genomics, transcriptomics, proteomics, and other omic data enables researchers to identify deeper biological insights, improve biomarker discovery, and accelerate precision medicine. A comprehensive multi-omic strategy helps transform complex datasets into actionable discoveries. […]
Understanding Immunogenicity in AAV Gene Therapyn
As AAV-based gene therapies advance into clinical development, managing immunogenicity risk has become essential to ensuring patient eligibility, therapeutic durability, and regulatory approval. This expert-authored white paper delivers a practical, science-backed framework for building immunogenicity assays that are analytically rigorous, clinically relevant, and globally aligned. Whether you’re designing early-phase protocols or preparing for global filings, […]
The Family Medical Leave Act (FMLA) Employer Handbook
Leave and absence management is changing as regulations change and employee demand for strong leave programs increases. Yet for many employers, the complexities of the Family and Medical Leave Act can make adapting to the current leave landscape a difficult task. Our updated 2021 FMLA guide will help employers and their HR professionals understand and […]
Navigating the Era of the Single Pivotal Clinical Trial
The US Food and Drug Administration (FDA) has signaled that relying on a single pivotal trial, rather than two, may become a more commonly acceptable pathway to market authorization. There are significant benefits for sponsors, potentially reducing the cost and complexity of running two trials as well as time to market, which puts lifesaving treatments […]
Policy, Pricing and the Changing Economics of Orphan Drugs
Despite policy and pricing turmoil across the pharmaceutical industry, orphan drug sales continue to rise steadily and remain stable for most of the market’s leading companies. In fact, important policy wins are supporting strong sales trajectories. But orphan drug developers must navigate carefully as they confront a temperamental FDA and compete for attention with blockbusters […]